Q1 Earnings Forecast for Clene Issued By Roth Capital

Clene Inc. (NASDAQ:CLNN) – Equities researchers at Roth Capital issued their Q1 2025 earnings estimates for Clene in a research report issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff expects that the company will post earnings of ($0.86) per share for the quarter. The consensus estimate for Clene’s current full-year earnings is ($5.26) per share. Roth Capital also issued estimates for Clene’s Q2 2025 earnings at ($0.86) EPS, Q3 2025 earnings at ($0.85) EPS and Q4 2025 earnings at ($0.75) EPS.

A number of other equities analysts have also weighed in on CLNN. Canaccord Genuity Group lowered their price target on shares of Clene from $86.00 to $83.00 and set a “buy” rating on the stock in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $31.00 price objective on shares of Clene in a report on Thursday. Finally, EF Hutton Acquisition Co. I raised shares of Clene to a “strong-buy” rating in a research note on Tuesday, September 10th.

Clene Trading Down 2.7 %

CLNN opened at $4.69 on Friday. The company has a fifty day moving average of $5.46 and a two-hundred day moving average of $6.05. The company has a quick ratio of 0.99, a current ratio of 0.99 and a debt-to-equity ratio of 1.66. Clene has a fifty-two week low of $3.82 and a fifty-two week high of $12.00.

Insider Transactions at Clene

In other Clene news, insider Mark Mortenson purchased 20,512 shares of Clene stock in a transaction on Monday, September 30th. The shares were purchased at an average cost of $4.75 per share, with a total value of $97,432.00. Following the completion of the transaction, the insider now directly owns 28,949 shares in the company, valued at approximately $137,507.75. This represents a 243.12 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David J. Matlin acquired 92,307 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were purchased at an average price of $4.75 per share, for a total transaction of $438,458.25. Following the purchase, the director now directly owns 444,491 shares of the company’s stock, valued at approximately $2,111,332.25. This trade represents a 26.21 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 25.10% of the company’s stock.

Institutional Trading of Clene

An institutional investor recently bought a new position in Clene stock. Castleview Partners LLC bought a new stake in shares of Clene Inc. (NASDAQ:CLNN) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 12,783 shares of the company’s stock, valued at approximately $59,000. Castleview Partners LLC owned about 0.19% of Clene at the end of the most recent reporting period. 23.28% of the stock is currently owned by institutional investors.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.